my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
01-24-2011: The Lead Discovery Center GmbH (LDC), a small molecule drug discovery spin-off of Max Planck Innovation GmbH, announced that it has signed a cooperation agreement with Merck KGaA for the discovery of kinase inhibitors as potential cancer treatments.
The collaboration is supported by the German Ministry of Education and Research (BMBF) under the BioPharma initiative to strengthen the pharmaceutical value chain in Germany.
Using an innovative kinase technology platform originating from the Chemical Genomics Centre of the Max Planck Society (CGC, Dortmund), Merck Serono, a division of Merck KGaA, and the LDC aim to identify inhibitory compounds against at least one undisclosed kinase target and advance them through the drug discovery process up to pharmaceutical lead compounds.
Kinases are key components of biochemical signalling pathways that control cellular growth, metabolism and differentiation. They have therefore become prime targets for drug discovery and development in many diseases, especially in oncology. “Our proprietary technology allows for the identification of innovative allosteric kinase inhibitors that hold strong potential for improved potency and selectivity,” says Prof. Dr. Daniel Rauh, group leader at the CGC. “We are excited about the alliance between the LDC and Merck Serono as it provides us with the unique chance to translate our approach into application.”
Under the terms of the agreement, the LDC and Merck Serono will work closely together, with each partner contributing its particular expertise and infrastructure as well as their own resources in the fields of assay development, screening, medicinal chemistry and pharmacology.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a pharma partner. The agreement grants Bayer Sch ... more
Lead Discovery Center and Merck KGaA Enter Collaboration for the Discovery of Anti-Cancer Compounds
The Lead Discovery Center GmbH (LDC), a small molecule drug discovery spin-off of Max Planck Innovation GmbH, announced that it has signed a cooperation agreement with Merck KGaA for the discovery of kinase inhibitors as potential cancer treatments. The collaboration is supported by the Ger ... more
InterMed Discovery Announces Collaboration Agreement With the Lead Discovery Center
InterMed Discovery (IMD announced the start of a screening project for the Lead Discovery Center GmbH (LDC), a Max-Planck-Innovation company. The LDC was founded in 2008 in close proximity to IMD at the University Campus at Dortmund and forms an essential part of Max-Planck-Innovation's Dru ... more
Lead Discovery Center GmbH (LDC)
The Lead Discovery Center GmbH (LDC) was jointly developed by Max Planck Innovation and the Max Planck Society as a novel approach to advance findings from excellent basic research into the development of novel medicines. With a world-class team of drug discovery experts and seasoned manage ... more
Q1/2012: Merck Total Revenues Increase 3.2% to € 2.6 Billion
“Merck delivered a reasonable operating performance in the face of a difficult year-over-year comparison,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck. “During the first quarter, we kicked off our efficiency program and announced the first planned initiatives as part of ... more
Merck PETACC-8 Study of Erbitux as Adjuvant Treatment in Colon Cancer Shows no Benefit
Merck announced results from an interim analysis of the Phase III clinical trial PETACC-81. The study investigated the potential clinical utility of Erbitux® (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor. The pre-specif ... more
Merck Announces Merck Serono Implementation Plans for Its Efficiency Program in Switzerland
Merck announced the efficiency measures it plans to take related to Merck Serono’s operations in Switzerland as part of the comprehensive transformation program announced by the company in February. Merck’s transformation program is focused on addressing unprecedented market shifts, increas ... more
Pyrodetect System: the Human(e) Alternative in Pyrogen Testing
A revolutionary test for the detection and quantification of pyrogens based on the monocyte activation test (MAT) more
ISOSLIDE® Reticulin control slides for histology
The ISOSLIDE® Reticulin Control Slides Box is a new product from Merck Millipore for the detection of reticulin fibers in histological tissue specimen more
Merck Millipore offers new, user-friendly packaging sizes for its microscopy products Entellan® new, Schiff´s reagent and OSTEOMOLL® more
Merck Millipore provides all expertise on chromatography in one place
With almost 400 pages, the catalog contains detailed information on a total of around 4,000 Merck Millipore chromatography products more
The Merck Group is a globally operating company in the areas of pharmaceuticals and chemicals. With 34,500 employees and more than 200 companies we are represented in 58 countries worldwide. Founded in 1668 in Darmstadt, Germany, the company sees the keys to success in entrepreneurial emplo ... more
Merck Schuchardt OHG, a 100% subsidiary of Merck KGaA, Germany, has, for the last 135 years, been one of the leading German producers and suppliers of organic intermediates, fine chemicals, reagents and solvents for laboratories, medium-sized and bulk production. more
Together EMD Biosciences and Merck Chemicals Ltd. are the research reagents group of the Performance and Life Science Chemicals division of Merck KGaA. Merck KGaA was founded in 1668 in Darmstadt, Germany, and now has more than 29,000 employees in 53 countries. EMD or Merck – why two names ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
